An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn – ALICE (PRODIGE89 – UCGI44 – ALICE)
Digestive and Liver Disease · 2026
DOI: 10.1016/j.dld.2026.08.030 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Digestive and Liver Disease, 2026. Verfasst von Octave Letissier und 23 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Centre Eugène Marquis, Rennes, France. Hauptthemen laut MEDLINE: Liver Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: French National Cancer Institute, AstraZeneca PLC, Unicancer.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Centre Eugène Marquis, Rennes, France.
- Gastroenterology, Saint Joseph Hospital, Marseille, France.
- Biostatistics, Eugène Marquis Center, Rennes, France.
- Digestive Hepato-oncology, Beaujon Hospital, Clichy, France.
- Hepatology, Rangueil Hospital, Toulouse, France.
- Gastroenterology, Poitiers Hospital, Poitiers, France.
Förderung
- French National Cancer Institute
- AstraZeneca PLC
- Unicancer
Zitieren
APA
Letissier, O., Adhoute, X., Campillo-Gimenez, B., Bouattour, M., Peron, J. M., Larbi, A., Ghiringhelli, F., Touchefeu, Y., Vallet-Pichard, A., Mineur, L., Boige, V., Saviano, A., Blanc, J. F., Amaddeo, G., Rosmorduc, O., Allaire, M., Decaens, T., Fiore, F. D., Khac, E. N., …, & Edeline, J. (2026). An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn – ALICE (PRODIGE89 – UCGI44 – ALICE). Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.08.030
Vancouver
Letissier O, Adhoute X, Campillo-Gimenez B, Bouattour M, Peron JM, Larbi A, et al. An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn – ALICE (PRODIGE89 – UCGI44 – ALICE). Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.08.030
BibTeX
@article{Letissier2026,
author = {Letissier, Octave and Adhoute, Xavier and Campillo-Gimenez, Boris and Bouattour, Mohamed and Peron, Jean-Marie and Larbi, Amina and Ghiringhelli, François and Touchefeu, Yann and Vallet-Pichard, Anaïs and Mineur, Laurent and Boige, Valérie and Saviano, Antonio and Blanc, Jean-Frédéric and Amaddeo, Giuliana and Rosmorduc, Olivier and Allaire, Manon and Decaens, Thomas and Fiore, Frédéric Di and Khac, Eric Nguyen and Monard, Laure and Pezzella, Veronica and Hariz, Aïcha Ben and Guiu, Boris and Edeline, Julien},
title = {An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn – ALICE (PRODIGE89 – UCGI44 – ALICE)},
journal = {Digestive and Liver Disease},
year = {2026},
doi = {10.1016/j.dld.2026.08.030}
}
EUVIMED